CoreCap Advisors’s Cullinan Oncology CGEM Stock Holding History

CoreCap Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-29	Closed	-$220	–	2849
2025 Q1	$220	Buy	+29	New	+$278	﹤0.01%	2934

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

CoreCap Advisors's CGEM Position: Q2 2025 in Review

CoreCap Advisors sold out of Cullinan Oncology (CGEM) in Q2 2025, closing a stake of 29 shares — an estimated $220 sold.

CoreCap Advisors first reported a position in CGEM in Q1 2025 and held it in 1 quarter. The position peaked at $220 in Q1 2025. 143 funds tracked by Wall St. Rank hold CGEM as of Q2 2025.

CoreCap Advisors reported no remaining Cullinan Oncology position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 29 Cullinan Oncology shares in Q2 2025, an estimated $220.
CoreCap Advisors first reported a position in Cullinan Oncology in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's Cullinan Oncology position peaked at $220 in Q1 2025.
143 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.